159992 创新药
已收盘 12-31 15:00:00
资讯
新帖
简况
西南证券：2025年创新药迎来β行情 2026年创新药行情将进入精选个股阶段
智通财经 · 11:24
西南证券：2025年创新药迎来β行情 2026年创新药行情将进入精选个股阶段
中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇
21世纪经济报道 · 08:10
中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇
安科生物：与创新药公司深度绑定提升竞争力
证券之星 · 12-30 20:52
安科生物：与创新药公司深度绑定提升竞争力
恒瑞医药六款创新药获临床试验批件，肿瘤管线再扩容
中金财经 · 12-30 20:26
恒瑞医药六款创新药获临床试验批件，肿瘤管线再扩容
破局创新药新周期：亿腾嘉和以逆向整合范式 锚定中国Biopharma领军之路
每日经济新闻 · 12-30 18:33
破局创新药新周期：亿腾嘉和以逆向整合范式 锚定中国Biopharma领军之路
引领中国创新药全球多中心同步临床开发新实践——访和誉医药董事长徐耀昌
经济参考网 · 12-30 18:22
引领中国创新药全球多中心同步临床开发新实践——访和誉医药董事长徐耀昌
海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理
智通财经 · 12-30 16:20
海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理
众生药业：呼吸系统疾病领域布局RSV创新药项目
证券之星 · 12-30 16:00
众生药业：呼吸系统疾病领域布局RSV创新药项目
港股创新药板块午后持续走弱，昭衍新药跌超7%
每日经济新闻 · 12-30 13:15
港股创新药板块午后持续走弱，昭衍新药跌超7%
奥赛康最新公告：奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议
证券之星 · 12-29 18:59
奥赛康最新公告：奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议
京新药业：LP（a）降脂创新药临床I期接近尾声
证券之星 · 12-29 18:09
京新药业：LP（a）降脂创新药临床I期接近尾声
海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组
智通财经 · 12-29 16:11
海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组
商保创新药目录出台后：“三除外”能否跑通？会否重演国谈药进院难？
第一财经 · 12-29 11:46
商保创新药目录出台后：“三除外”能否跑通？会否重演国谈药进院难？
跨国药企发起降价潮？港股通创新药逆市走低，520880溢价高企！机构力挺国产创新药：重点关注2026年Q1
新浪基金 · 12-29 11:07
跨国药企发起降价潮？港股通创新药逆市走低，520880溢价高企！机构力挺国产创新药：重点关注2026年Q1
每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲
证券之星 · 12-28
每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲
突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？
睿见Economy · 12-26
突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？
长城基金梁福睿：2026年创新药行情值得期待
新浪基金 · 12-26
长城基金梁福睿：2026年创新药行情值得期待
优宁维：创新药研发是公司产品主要应用领域之一
证券之星 · 12-24
优宁维：创新药研发是公司产品主要应用领域之一
中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇
21世纪经济报道 · 12-23
中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇
十年深耕：中国创新药授权交易从“爆发”迈向“长红”
21世纪经济报道 · 12-23
十年深耕：中国创新药授权交易从“爆发”迈向“长红”
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.831,"timestamp":1767164598000,"preClose":0.837,"halted":0,"volume":567649948,"delay":0,"changeRate":-0.0072,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.006,"latestTime":"12-31 15:00:00","open":0.836,"high":0.839,"low":0.83,"amount":473000000,"amplitude":0.0108,"askPrice":0.832,"askSize":7638,"bidPrice":0.831,"bidSize":27555,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.837,"symbolType":"fund","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":0.921,"lowLimit":0.753,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.22923,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2595371740","title":"西南证券：2025年创新药迎来β行情 2026年创新药行情将进入精选个股阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2595371740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595371740?lang=zh_cn&edition=full","pubTime":"2025-12-31 11:24","pubTimestamp":1767151452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，2025年初，港股企业陆续达成BD;港股创新药领先上涨;3月，《政府工作报告》提出“健全药品价格形成机制，制定创新药目录，支持创新药和医疗器械发展，A股创新药跟涨。5月随着PD1/VEGR双抗首付款12.5亿美金BD落地，创新药迎来加速上涨行情。随着三季度结束，创新药迎来高位调整。该行判断，2026年创新药板块将从普涨进入精选个股行情。2026年，该行看好医","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","BK1574","BK1161","BK0276","BK0188","BK0183","BK0012","600369","BK0028"],"gpt_icon":0},{"id":"2595745070","title":"中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745070","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595745070?lang=zh_cn&edition=full","pubTime":"2025-12-31 08:10","pubTimestamp":1767139800,"startTime":"0","endTime":"0","summary":"2025年，中国创新药行业的成绩单已跃然纸上：生物医药市场规模居全球第二，在研创新药约占全球比重达30%；创新资产的全球吸引力持续攀升，截至11月18日，国产创新药对外授权总金额突破千亿 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251231/c673654924.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251231/c673654924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2595797894","title":"安科生物：与创新药公司深度绑定提升竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2595797894","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595797894?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:52","pubTimestamp":1767099136,"startTime":"0","endTime":"0","summary":"证券之星消息，安科生物12月29日在投资者关系平台上答复投资者关心的问题。公司参股的博生吉公司、阿法纳公司等创新药公司在各自领域独树一帜，具有很强的竞争力，公司在参股这些公司的同时将会与这些创新药公司深度绑定，在新药研发、新药商业化等方面积极开展合作，以提升公司业务的整体性和核心竞争力。增资并购事项属于公司重大事项，请您关注公司披露的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000040833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK1161","BK0042","300009","BK0070","BK1574","06978","159992","BK0239"],"gpt_icon":0},{"id":"2595792596","title":"恒瑞医药六款创新药获临床试验批件，肿瘤管线再扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792596","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595792596?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:26","pubTimestamp":1767097566,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司及其子公司近日宣布，其自主研发及引进的六款抗肿瘤新药已获得国家药品监督管理局颁发的药物临床试验批准通知书，即将进入临床研究阶段。此次获批的药品包括SHR-4375注射液、阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、HRS-4642注射液及注射用SHR-9839，将联合开展一项针对晚期实体肿瘤患者的Ib/II期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31904557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2580892789.USD","LU1064131003.USD","LU1023057109.AUD","LU0359201885.HKD","LU2097828805.USD","LU0405327148.USD","LU1969619763.USD","LU2148510915.USD","LU1820825898.SGD","BK1574","LU1997244956.HKD","LU2097828474.EUR","LU1255011170.USD","LU1655091616.SGD","LU2328871848.SGD","01276","LU2580892862.HKD","LU0405327494.USD","BK0239","BK0060","LU2495084118.USD","06978","LU2543165471.USD","LU1146622755.USD","LU1580142542.USD","LU2097828631.EUR","159992","LU1781817850.SGD","BK0183","BK0188","BK0012","BK1161","LU1064130708.USD","LU2488822045.USD","600276","BK0028","LU0359202008.SGD","LU2097828557.USD","BK0196","LU2097828714.EUR","BK1191","LU2289578879.USD","LU1997245177.USD","LU0359201612.USD","LU1328615791.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2595967957","title":"破局创新药新周期：亿腾嘉和以逆向整合范式 锚定中国Biopharma领军之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2595967957","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595967957?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:33","pubTimestamp":1767090780,"startTime":"0","endTime":"0","summary":"12月30日，港股18A板块迎来里程碑事件——亿腾医药集团有限公司反向收购嘉和生物药业（开曼）控股有限公司的交易尘埃落定。双方通过换股合并，共同组建全新上市平台——亿腾嘉和医药集团有 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251230/c673633590.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251230/c673633590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2595796611","title":"引领中国创新药全球多中心同步临床开发新实践——访和誉医药董事长徐耀昌","url":"https://stock-news.laohu8.com/highlight/detail?id=2595796611","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595796611?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:22","pubTimestamp":1767090149,"startTime":"0","endTime":"0","summary":"近日，和誉医药（02256.HK）自主研发的一类新药贝捷迈（盐酸匹米替尼胶囊）获国家药品监督管理局批准上市，填补了国内腱鞘巨细胞瘤（TGCT）系统疗法的临床空白。《经济参考报》记者走进和誉医药，探寻在这场里程碑式的突破背后，和誉医药董事长兼CEO徐耀昌博士带领团队，用科学坚守与务实创新，书写了中国医药产业高质量发展的“生动答卷”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605811750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","IE00B543WZ88.USD","BK1574","02256","IE00BPRC5H50.USD","LU2488822045.USD","LU2778985437.USD","LU2476274720.SGD","159938","LU2476274308.USD","BK1515","09939","BK1161","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2595670427","title":"海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670427?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:20","pubTimestamp":1767082829,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《受理通知书》，涉及产品：“HSK50042”、“HSK55879”。本次申请为HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请，有望为呼吸疾病患者提供一种高效、安全的新型治疗选择。HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物，拟用于代谢系统疾病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","IND","BK0077","BK0028","BK0239","BK0033","BK1574","BK1161","BK0188","06978","002653"],"gpt_icon":0},{"id":"2595604767","title":"众生药业：呼吸系统疾病领域布局RSV创新药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2595604767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595604767?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:00","pubTimestamp":1767081652,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请详细介绍下呼吸道合胞病毒创新药进度如何了众生药业回复：您好！在呼吸系统疾病领域，公司挖掘未被满足的临床需求，布局了用于治疗呼吸道合胞病毒（RSV）感染的化学小分子创新药项目，其对多种RSV病毒株的体内外抗病毒活性强、药代特性优秀、化合物毒性低。目前该项目正处于临床前研究阶段，后续将按计划有序推进项目开发工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000021579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK1161","BK0239","06978","BK0077","BK1574","159992"],"gpt_icon":0},{"id":"2595662547","title":"港股创新药板块午后持续走弱，昭衍新药跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595662547","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595662547?lang=zh_cn&edition=full","pubTime":"2025-12-30 13:15","pubTimestamp":1767071744,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月30日，港股创新药板块午后持续走弱，昭衍新药跌超7%，荣昌生物、康龙化成、歌礼制药-B跌超5%，凯莱英、诺诚健华跟跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605538957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605538957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","BK1141","06978","159992","BK0216","BK1576","BK1574","06127","BK1161"],"gpt_icon":0},{"id":"2595784432","title":"奥赛康最新公告：奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784432","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784432?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:59","pubTimestamp":1767005993,"startTime":"0","endTime":"0","summary":"奥赛康公告称，公司子公司奥赛康药业与阿诺医药达成许可引进协议，将获得阿诺医药在研的1类创新药AN9025项目在许可区域内的开发、生产及商业化的独占权益。奥赛康药业将向阿诺医药支付与若干销售里程碑事件达成相关的付款，总计不超过11.28亿元人民币。AN9025项目为新型口服泛RAS抑制剂，用于治疗RAS突变型实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900029021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1574","159992","06978","BK0239","002755","BK1161"],"gpt_icon":0},{"id":"2595789267","title":"京新药业：LP（a）降脂创新药临床I期接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2595789267","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595789267?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:09","pubTimestamp":1767002953,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：京新药业的 JX2201 目前处于 I期临床末尾，临床指标是不是达到预期效果，目前公司有没有准备启动2期临床的计划。同时请问公司这款创新药在国内同行业中属于第几梯队在国际上属于什么层次？公司的LP降脂创新药临床I期接近尾声，盐酸卡利拉嗪胶囊已提交上市申请，正常推进中，具体情况敬请关注定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900025460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","159992","BK1161","06978","BK1574","BK0239"],"gpt_icon":0},{"id":"2595788890","title":"海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788890","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788890?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:11","pubTimestamp":1766995885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。NWRD06注射液是目前全球首个针对肝癌特异性靶点GPC3并进入Ⅱ期临床阶段的治疗性核酸药物，其通过激活特异性T细胞免疫清除肿瘤细胞的机制具有创新性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","002099","BK0028","BK0239","BK1161","BK0192","BK0188","BK0077","06978"],"gpt_icon":0},{"id":"2595206531","title":"商保创新药目录出台后：“三除外”能否跑通？会否重演国谈药进院难？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595206531","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595206531?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:46","pubTimestamp":1766979960,"startTime":"0","endTime":"0","summary":"自12月7日国家医保谈判结束，次日四川省即印发基本医保目录、商业健康保险创新药目录的挂网采购通知。对于首次发布的商业健康保险创新药目录，业界更为关心的，是该目录纳入的19种高值创新药接下来将如何“闯三关”，也即进院、开方、支付这三道真正的难关。 但目前尚无明确的细则，指导“三除外”政策落地。 商保目录出台后，“三除外”如何实现，商保创新药是否会遭遇与早年国谈药相似的进院困境？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-29/doc-inhemqaw5053913.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-29/doc-inhemqaw5053913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2595053262","title":"跨国药企发起降价潮？港股通创新药逆市走低，520880溢价高企！机构力挺国产创新药：重点关注2026年Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2595053262","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595053262?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:07","pubTimestamp":1766977620,"startTime":"0","endTime":"0","summary":"12月29日，港股开市走高，恒指飘红，恒科指一度涨超2%。普涨之下，创新药板块意外走低，港股通创新药ETF盘中跌逾1.5%，权重股石药集团跌逾2%，康方生物、中国生物制药等龙头股均跌逾1%。 不过港股通创新药ETF场内持续溢价交易，显示或有低吸资金逢跌吸筹。 消息面，2025年年末，一场由跨国药企诺和诺德与礼来主动发起的降价潮，在政府采购平台、电商平台悄然上演，实际成交价格较半年前近乎“腰斩”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-29/doc-inhemqas7995635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","159992","520880"],"gpt_icon":0},{"id":"2594326242","title":"每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2594326242","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594326242?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:35","pubTimestamp":1766864112,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，联环药业报收于18.3元，较上周的17.98元上涨1.78%。本周，联环药业12月26日盘中最高价报18.48元。联环药业于2025年12月22日召开2025年第三季度业绩说明会，管理层回应投资者关切，表示持续推进呼吸系统、肿瘤、内分泌等领域创新药研发，多个项目处于临床阶段，其中LH-1801预计2026年一季度揭盲。创新药LH-1801处于III期临床52周随访阶段，预计2026年一季度揭盲。该药品用于治疗成人原发性高血压，2024年度全国样本医院销售额为5,873.19万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK1574","BK0239","06978","600513"],"gpt_icon":0},{"id":"2594262003","title":"突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594262003","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594262003?lang=zh_cn&edition=full","pubTime":"2025-12-26 15:51","pubTimestamp":1766735460,"startTime":"0","endTime":"0","summary":" “为中国经济点赞——企业家之夜”已于12月17日正式启动，目前点赞活动正在火热进行中。 在科技飞速发展的当下，创新药研发作为生命科学领域的关键战场，承载着人类对抗疾病、追求健康的美好愿景。药明康德董事长李革、江苏恒瑞医药董事长孙飘扬、康方生物主席夏瑜、百利天恒药业董事长朱义，谁将为人类赢得下一场生命之战？","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-26/doc-inhecipr0850194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2594193261","title":"长城基金梁福睿：2026年创新药行情值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2594193261","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594193261?lang=zh_cn&edition=full","pubTime":"2025-12-26 14:57","pubTimestamp":1766732220,"startTime":"0","endTime":"0","summary":"近日，长城基金举办了2026年度投资策略会，长城医药产业基金经理梁福睿在会上就创新药领域的热门问题展开了深度探讨。 展望2026年，梁福睿依旧看好创新药行情。梁福睿认为，2026年创新药有望兼具Beta和Alpha，是双层共振的方向。叠加2026年全球流动性环境可能总体宽裕，以及自身产业趋势加持、Alpha变化支撑，明年创新药值得期待。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-26/doc-inheccft0928983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2593422894","title":"优宁维：创新药研发是公司产品主要应用领域之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422894?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:05","pubTimestamp":1766559928,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司有没有向创新药或者脑机接口进军布局？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。创新药研发是公司产品的主要应用领域之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0250","301166","06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2593556495","title":"中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇","url":"https://stock-news.laohu8.com/highlight/detail?id=2593556495","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593556495?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:16","pubTimestamp":1766481360,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 韩利明2025年，中国创新药行业的成绩单已跃然纸上：生物医药市场规模居全球第二，在研创新药约占全球比重达30%；创新资产的全球吸引力持续攀升，截至11月18日，国产创新 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251223/c673440107.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251223/c673440107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2593498324","title":"十年深耕：中国创新药授权交易从“爆发”迈向“长红”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593498324","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593498324?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:24","pubTimestamp":1766478262,"startTime":"0","endTime":"0","summary":"BD（商务拓展），曾在生物医药领域融资市场持续收紧的“资本寒冬”中，为中国生物科技公司（Biotech）带来了新的募资契机。2025年，BD掀起了前所未有的热潮。央视财经数据显示，截至2025年11月18日，国产创新药对外授权总金额已突破千亿美元，相较于2024年实现了翻倍式增长。手握优质BD项目的Biotech迎来了股价上涨、IPO畅通等红利，更有不少企业提前预告BD进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599517231.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599517231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","BK1574","159992"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767188102701,"stockEarnings":[{"period":"1week","weight":-0.0176},{"period":"1month","weight":-0.0456},{"period":"3month","weight":-0.1371},{"period":"6month","weight":0.0295},{"period":"1year","weight":0.1789},{"period":"ytd","weight":0.2009}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}